Join ISPE Now for Added Benefits

Posted by ISPE Boston
On May 14, 2020

During times like these ISPE Boston recognizes the vital role our members play in our development and mission. We’d like to show our appreciation by rolling out some membership incentives starting May 15th, 2020 through July 15th, 2020. Anyone who renews their membership or is joining the Boston Area Chapter for the first time will […]

Webinar De-Mystifies Water Purification

Posted by Janet Tice
On May 14, 2020

The Boston Area Chapter webinar series is charging ahead, with its second offering, “Taking the Guesswork out of Your Water Purification System,” airing last Thursday. In contrast to the topical COVID-19 theme of the previous week, webinar number two was a return to biopharm fundamentals. The back-to-basics look at water purification was presented by Brian […]

Moderna and Lonza in Deal to Manufacture Moderna’s Coronavirus mRNA Vaccine

Posted by ISPE Boston
On May 6, 2020

Moderna and Lonza have announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future. Under the terms of the agreement, the companies plan to establish manufacturing suites at Lonza’s facilities in the U.S. and Switzerland for the […]

Alexion in $1.4 Billion Acquisition

Posted by ISPE Boston
On May 6, 2020

Alexion has announced it will acquire Portola, a commercial-stage biopharma focused on life-threatening blood-related disorders. Portola’s commercialized medicine, Andexxa (marketed as Ondexxya in Europe) is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in […]

Pfizer and BioNTech Begin Phase 1/2 Trial for COVID-19 Vaccine

Posted by ISPE Boston
On May 6, 2020

Pfizer and BioNTech have dosed the first participants in the U.S. and Germany in the Phase 1/2 clinical trial for the BNT162 COVID-19 vaccine program. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. Pfizer and BioNTech’s development […]

Chapter Member Anniversaries: May 2020

Posted by ISPE Boston
On May 5, 2020

Please congratulate the following members celebrating milestone anniversaries in May 2020. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Karen Conte, Pfizer Timothy W. Crowley, Sentrol, Inc. Michael J. Denault, Denault Associates Daniel M. Duffy, Jr., Sanofi John H. Evers, MS, Lantheus Medical Imaging Joshua Froimson, AbbVie […]

Welcome New Members April 2020!

Posted by ISPE Boston
On May 5, 2020

We would like to introduce the Members who joined ISPE in April 2020, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

New Normal, New Webinar Programming!

Posted by ISPE Boston
On April 30, 2020

The Boston Area Chapter is proud to kick off a series of Thursday webinars in a joint venture with our sister Chapter, Delaware Valley. The first installment on April 23 took as its topic the very reason why webinars have replaced in-person programming: the COVID-19 pandemic. With over 200 attendees tuning in, a group of […]

COVID-19 Webinar Highlights Industry Response

Posted by Caren Jenkins
On April 30, 2020

Last Thursday’s webinar panelists delved deep into the coronavirus pandemic, with a focus on the biopharma industry’s response. Steve Fadden, Georgia Keresty and Marc Pelletier (of J&J, Takeda and CRB Consulting Engineers, respectively) began by describing when they first became aware of the pandemic and what they and their organizational teams did to respond. They […]

Waltham’s TScan Teams with Novartis on T Cell Receptor Cancer Treatments

Posted by ISPE Boston
On April 21, 2020

TScan Therapeutics has announced it will partner with Novartis to discover and develop novel T cell receptor (TCR) engineered T cell therapies. TCR therapies reprogram a patient’s own T cells to recognize shared cancer targets. The collaboration includes an upfront technology access fee and research funding totaling $30 million, and potential milestone payments contingent on […]

Page 67 of 118«‹65 666768 69 ›»